Newsroom

DBV Technologies announces the filing of its “Document de Base” with the French Autorité des marchés financiers (the “AMF”) for proposed Initial Public Offering on the regulated market of NYSE Euronext in Paris

Download official press release (501.4 KB)

Bagneux, France, January 31 , 2012 – DBV Technologies, originator of Viaskin®, a new standard in the treatment of allergy, announces today the filing of its Document de Base with the AMF under number I. 12-004. dated January 30, 2012.

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue constantly growing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. This process, known as Viaskin®, allows for significant reductions of risks linked to generalized allergic reactions. This unique and highly innovative method has been part of an important development leading to a product currently at an industrial stage that has already proven to be safe for use in humans.

The Company focuses on the development of three products:

• Viaskin® Peanut for the treatment of peanut allergy in adults and children, for which a Phase II clinical study started in France in 2010;
• Viaskin® Milk for the treatment of cow's milk allergy in children, for which the launch of a Phase II clinical study is planned for 2013;
• Viaskin® HDM for the treatment of dust mites allergy in young children – poorly covered by current and available desensitization methods - for which a Phase I clinical study will start in 2013, capitalizing on earlier works performed on the above products.

In total, the three allergies DBV Technologies is focusing on represent potential peak sales of over $ 5 billion, as estimated by the Company. The company will also pursue new growth opportunities in other possible applications in the field of allergy (egg, seafood ...) and other therapeutic areas (vaccines, immune diseases...).

The filing of the Document de Base is the first step in the proposed IPO of DBV Technologies on the regulated market of NYSE Euronext in Paris, which is expected during 2012, depending on market conditions and subject to the approval (visa) of the AMF on the prospectus relating to the operation.

The Document de Base of DBV Technologies is available free of charge upon request from DBV Technologies, Green Square, 80/84 rue des Meuniers - 92220 Bagneux - FRANCE and on the DBV Technologies’ website (www.dbv-technologies.com) as well on the AMF’s (www.amf-france.org). DBV Technologies would like to draw investors’ attention to Section 4 "Risk Factors" of the Document de Base.

• Share